Matsuo, Koji http://orcid.org/0000-0002-6232-8701
Matsuzaki, Shinya
Nusbaum, David J.
Roman, Lynda D.
Wright, Jason D.
Harter, Philipp
Klar, Maximilian
Funding for this research was provided by:
Ensign Endowment for Gynecologic Cancer Research
Article History
Received: 18 November 2020
Accepted: 17 February 2021
First Online: 1 April 2021
Disclosure
: The following disclosures are declared, outside the submitted work: Jason D. Wright is a consultant for Clovis Oncology and has undertaken research funding for Merck. Lynda D. Roman is a consultant for Quantgene. Koji Matsuo has received honorarium from Chugai, textbook editorial expenses from Springer, and investigator meeting attendance expenses from VBL therapeutics. Shinya Matsuzaki has received research funding from MSD. Philipp Harter has received personal fees, non-financial support, honoraria for lectures, advisory board fees, and travel support from AstraZeneca and Roche; non-financial support and travel support from Medac; personal fees, honoraria for lectures, and advisory board fees from Tesaro and PharmaMar; personal fees and honoraria for advisory board participation from Clovis and Lilly; personal fees and honoraria for lectures from Stryker; and personal fees and honoraria for advisory board participation from Immunogen. Maximilian Klar has received advisory board fees from Tesaro and GSK. David J. Nusbaum has no conflicts of interest to declare.